特一药业：2025年前三季度净利增近10倍

Core Insights - The company reported a significant increase in revenue and net profit for the first three quarters of 2025, with revenue reaching 692 million yuan, a year-on-year growth of 51.86% [1] - Net profit attributable to shareholders surged to 65.22 million yuan, marking an astonishing increase of 985.18% [1] - The net profit after excluding non-recurring gains and losses was 62.81 million yuan, reflecting a staggering growth of 2508.06% [1] Financial Performance - Basic earnings per share rose from 0.01 yuan to 0.13 yuan, an increase of 1200% [1] - Operating cash flow net amount reached 192 million yuan, up 599.53% year-on-year [1] Business Strategy - The company completed the establishment of its self-operated sales team in 2025, leading to a gradual recovery in sales of its core product, cough relief tablets [1] - Marketing reforms have shown significant results, contributing to the overall performance growth [1] Investment and Shareholder Confidence - The company invested heavily in brand building, with sales expenses amounting to 236 million yuan, a year-on-year increase of 149.72% [1] - The company actively promoted a share repurchase plan, having repurchased 13.73 million shares, accounting for 2.68% of the total share capital, with a total repurchase amount exceeding 100 million yuan [1]